Decentralized Clinical Trials Market Overview, Key Trends, and Major Player Analysis

The decentralized clinical trials industry is rapidly evolving, driven by technological advancements and changing healthcare needs. As clinical research shifts toward more flexible and patient-centric models, the market is set to experience significant expansion in the coming years. Below, we explore the market's value projections, key players, emerging trends, and the various segments defining this dynamic sector.

Projected Market Value and Growth Trajectory for Decentralized Clinical Trials
The decentralized clinical trials market is anticipated to grow substantially, reaching $19.55 billion by 2030. This represents a robust compound annual growth rate (CAGR) of 17.3%. The expansion is fueled by several factors, including the rising adoption of hybrid trial designs that combine traditional and remote methodologies, a growing need for accelerated drug development timelines, and the broadening scope of global virtual trials. Additionally, the increasing integration of AI-driven trial optimization and a stronger emphasis on diverse patient recruitment contribute significantly to market growth. Key trends expected to shape this sector include widespread use of remote patient monitoring devices, greater reliance on virtual trial platforms, expansion of data collection through wearable technologies, real-time analytics implementation, and a more pronounced focus on patient-centric trial frameworks.

Download a free sample of the decentralized clinical trials market report:
https://www.thebusinessresearchcompany.com/report/decentralized-clinical-trials-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Key Companies Influencing the Decentralized Clinical Trials Market
Several prominent organizations are actively shaping the decentralized clinical trials landscape. Notable players include Walgreens Boots Alliance Inc., Pfizer Inc., Oracle Corporation, Thermo Fisher Scientific Inc., IQVIA Holdings Inc., and Labcorp Holdings Inc. Others such as ICON Public Limited Company, Dassault Systèmes SE, LEO Pharma A/S, Verily Life Sciences LLC, ProPharma, Signant Health Holding Corp., PCM Trials, Huma Therapeutics Limited, Medable Inc., Science 37 Inc., Obvio Health, EmVenio Research Inc., Grove AI Inc., and Phesi Inc. are also key contributors.

In a significant move within the market, Signant Health, a US-based provider specializing in evidence generation for innovative clinical trials, acquired DSG Inc. in July 2023. This acquisition aims to strengthen Signant Health's eClinical offerings by incorporating DSG's unified electronic data capture (EDC) and direct data capture (DDC) platform. The integration will support both traditional and decentralized clinical trials more comprehensively, enhancing operational efficiency, streamlining processes, and improving digital solutions for sponsors, trial sites, and contract research organizations (CROs). DSG Inc., based in the US, is recognized for its cutting-edge technology that unifies EDC and DDC within an eClinical suite tailored for decentralized and site-based trials.

The decentralized clinical trials industry is rapidly evolving, driven by technological advancements and changing healthcare needs. As clinical research shifts toward more flexible and patient-centric models, the market is set to experience significant expansion in the coming years. Below, we explore the market's value projections, key players, emerging trends, and the various segments defining this dynamic sector.

Projected Market Value and Growth Trajectory for Decentralized Clinical Trials
The decentralized clinical trials market is anticipated to grow substantially, reaching $19.55 billion by 2030. This represents a robust compound annual growth rate (CAGR) of 17.3%. The expansion is fueled by several factors, including the rising adoption of hybrid trial designs that combine traditional and remote methodologies, a growing need for accelerated drug development timelines, and the broadening scope of global virtual trials. Additionally, the increasing integration of AI-driven trial optimization and a stronger emphasis on diverse patient recruitment contribute significantly to market growth. Key trends expected to shape this sector include widespread use of remote patient monitoring devices, greater reliance on virtual trial platforms, expansion of data collection through wearable technologies, real-time analytics implementation, and a more pronounced focus on patient-centric trial frameworks.

Download a free sample of the decentralized clinical trials market report:
https://www.thebusinessresearchcompany.com/report/decentralized-clinical-trials-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Apr_PR
Key Companies Influencing the Decentralized Clinical Trials Market
Several prominent organizations are actively shaping the decentralized clinical trials landscape. Notable players include Walgreens Boots Alliance Inc., Pfizer Inc., Oracle Corporation, Thermo Fisher Scientific Inc., IQVIA Holdings Inc., and Labcorp Holdings Inc. Others such as ICON Public Limited Company, Dassault Systèmes SE, LEO Pharma A/S, Verily Life Sciences LLC, ProPharma, Signant Health Holding Corp., PCM Trials, Huma Therapeutics Limited, Medable Inc., Science 37 Inc., Obvio Health, EmVenio Research Inc., Grove AI Inc., and Phesi Inc. are also key contributors.

In a significant move within the market, Signant Health, a US-based provider specializing in evidence generation for innovative clinical trials, acquired DSG Inc. in July 2023. This acquisition aims to strengthen Signant Health's eClinical offerings by incorporating DSG's unified electronic data capture (EDC) and direct data capture (DDC) platform. The integration will support both traditional and decentralized clinical trials more comprehensively, enhancing operational efficiency, streamlining processes, and improving digital solutions for sponsors, trial sites, and contract research organizations (CROs). DSG Inc., based in the US, is recognized for its cutting-edge technology that unifies EDC and DDC within an eClinical suite tailored for decentralized and site-based trials.

Technological Innovation Driving the Decentralized Clinical Trials Sector
Advances in wearable technology and software integration are transforming decentralized clinical trials, particularly in enabling personalized functional rehabilitation. Companies are developing software-powered wearable bionic devices that combine functional electrical stimulation with real-time mobility tracking. These innovations aim to enhance walking ability, strength, and independence in patients with neuromuscular impairments.

For example, in May 2024, CIONIC, a neurotechnology company in the U.S., introduced enhancements to its FDA-cleared Cionic Neural Sleeve. This device offers new functional exercises and detailed activity tracking for individuals with conditions such as multiple sclerosis, stroke, and spinal cord injury. The lightweight and durable leg sleeve combines gait laboratory diagnostics with electrical stimulation and operates via smartphone. It also supports software-driven updates that can be deployed remotely to all users, empowering patients to improve their mobility and perform daily activities with greater independence.

Segments Defining the Decentralized Clinical Trials Market
This market is segmented across various dimensions to provide a detailed understanding of its structure:

1) By Type:
- Interventional
- Observational
- Expanded Access

2) By Technology Used:
- Wearable Devices
- Mobile Health Applications
- Telemedicine Platforms
- Electronic Data Capture Systems

3) By Study Phase:
- Phase I
- Phase II
- Phase III
- Phase IV

4) By Therapeutic Area:
- Oncology
- Cardiology
- Neurology
- Infectious Diseases

5) By End-User:
- Pharmaceutical Companies
- Biotechnology Firms
- Contract Research Organizations
- Regulatory Authorities
- Academic and Research Institutions

Further breakdown includes:

By Interventional Trials: Randomized Controlled Trials (RCTs), Non-Randomized Trials, Adaptive Clinical Trials, Pragmatic Clinical Trials
By Observational Studies: Cohort, Case-Control, Cross-Sectional, Prospective, Retrospective, Longitudinal
By Expanded Access: Treatment Investigational New Drug (IND) Applications, Intermediate-Size Patient Population IND Applications, Single-Patient IND Applications, Emergency Use IND Applications

This comprehensive segmentation highlights the diversity and complexity of decentralized clinical trials, demonstrating how they cater to various study designs, technologies, phases, and therapeutic focuses.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.